Hep B Trials Should Use Composite Endpoint, Not Just Histology – FDA Cmte.
Executive Summary
FDA should consider using composite markers instead of liver histology as the primary endpoint for hepatitis B trials, members of FDA's Antiviral Drug Products Advisory Committee suggested